Method and kit for determining in vitro the probability for an individual to suffer from colorectal cancer

Patent metadata

Field	Value
Publication number	US-9689041-B2
Application number	US-201214007439-A
Country	US
Kind code	B2
Filing date	Mar 23, 2012
Priority date	Mar 25, 2011
Publication date	Jun 27, 2017
Grant date	Jun 27, 2017

Abstract

The present invention provides a method for determining in vitro, in a peripheral blood sample, the probability for an individual to suffer from a colorectal cancer, using the comparison of the amount of expression products of nucleic acids of genes of the individual to be tested with the amount of expression products of nucleic acids of the same genes obtained from a CRC group of patients constituting the positive control and with the amount of expression products of nucleic acids of the same genes obtained from a CNC group of individuals constituting the negative control; and a kit comprising specific binding partners for said expression products.

First claim

The invention claimed is:

1. A method comprising:
measuring an amount of at least one expression product expressed from at least one target gene selected from the group consisting of the FAM198B, MYBL1, PDZK11P1, and VSIG10 genes,
wherein the amount of the expression product is measured using a peripheral blood sample obtained for in vitro colorectal cancer testing from an individual.

2. The method of claim 1 , wherein the amount of the expression product is measured by an assay that comprises contacting the expression product with at least one binding partner specific for the expression product.

3. The method of claim 1 , comprising measuring the amounts of a plurality of expression products expressed from a plurality of target genes selected from the group consisting of the FAM198B, MYBL1, PDZK11P1, and VSIG10 genes, wherein the amounts of the expression products are measured by an assay that comprises contacting the expression products with binding partners specific for the expression products.

4. The method of claim 1 , wherein the amounts of fewer than 50 expression products are measured.

5. The method of claim 1 , comprising measuring the amounts of expression products expressed from the NEAT1, FAM198B, ITGAM, MYBL1, SIAH2, PDZK11P1, and VSIG10 genes.

6. The method of claim 1 , wherein the expression product is an RNA transcript or a polypeptide.

7. The method of claim 1 , wherein the amount of the expression product is measured using at least one of hybridization, amplification, or sequencing.

8. The method of claim 1 , wherein the expression product is mRNA that is hybridized with at least one probe, at least one primer, or a combination thereof.

9. The method of claim 1 , wherein cDNA of the expression product is hybridized with at least one probe, at least one primer, or a combination thereof.

10. The method of claim 1 , wherein cRNA of the expression product is hybridized with at least one probe, at least one primer, or a combination thereof.

11. The method of claim 1 , wherein the expression product is a polypeptide that is bound by at least one ligand specific for the polypeptide.

12. The method of claim 11 , wherein the ligand is an antibody.

13. The method of claim 11 , wherein the ligand is an affinity protein.

14. The method of claim 11 , wherein the polypeptide is bound by at least two ligands specific for the polypeptide.

15. A kit for in vitro colorectal cancer testing, comprising:
one or more binding partners specific for from 1 to no more than 50 expression products that include at least one binding partner specific for an expression product expressed from a target gene selected from the group consisting of the FAM198B, MYBL1, PDZK11P1, and VSIG10 genes, wherein the binding partner is attached to a detectable label or solid substrate.

16. The kit of claim 15 , further comprising instructions for performing in vitro colorectal cancer testing using a peripheral blood sample obtained from an individual.

17. The kit of claim 15 , comprising a plurality of binding partners specific for a plurality of expression products expressed from a plurality of target genes selected from the group consisting of the FAM198B, MYBL1, PDZK11P1, and VSIG10 genes.

18. The kit of claim 15 , comprising a combination of binding partners specific for the expression products expressed from the NEAT1, FAM198B, ITGAM, MYBL1, SIAH2, PDZK11P1, and VSIG10 genes.

19. The kit of claim 15 , wherein the one or more binding partners include at least one hybridization probe.

20. The kit of claim 15 , wherein the one or more binding partners include at least one hybridization probe and at least one primer.

21. The kit of claim 15 , wherein the one or more binding partners include at least one hybridization probe and a pair of primers.

22. The kit of claim 15 , wherein the one or more binding partners include at least one ligand.

23. The kit of claim 15 , wherein the one or more binding partners include at least one antibody or affinity protein.

24. The kit of claim 15 , wherein the one or more binding partners include at least two ligands specific for the same expression product.

25. The method of claim 1 , further comprising measuring an amount of at least one expression product expressed from at least one of the NEAT1, SIAH2, and ITGAM target genes.

26. A method comprising:
measuring amounts of a plurality of expression products expressed from (i) at least one of the NEAT1 and ITGAM target genes, and (ii) at least one target gene selected from the group consisting of the FAM198B, MYBL1, SIAH2, PDZK11P1, and VSIG10 genes,
wherein the amounts of the expression products are measured using a peripheral blood sample obtained for in vitro colorectal cancer testing from an individual.

27. A method comprising:
measuring amounts of a plurality of expression products expressed from a plurality of target genes selected from the group consisting of the FAM198B, MYBL1, SIAH2, PDZK11P1, and VSIG10 genes,
wherein the amounts of the expression products are measured using a peripheral blood sample obtained for in vitro colorectal cancer testing from an individual.

Assignees

• Ye Xun
• Wu Fei
• Xu Qinghua
• Liu Fang
• Meng Xia
• Mougin Bruno
• Biomerieux Sa

Inventors

• Ye Xun
• Wu Fei
• Xu Qinghua
• Liu Fang
• Meng Xia
• Mougin Bruno

Classifications

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• G01N33/5308

  for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites · CPC title

• C12Q2600/158

  Expression markers · CPC title

• G01N2800/50

  Determining the risk of developing a disease · CPC title

• G01N33/57535

  of the large intestine, e.g. colon, rectum or anus · CPC title